AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05148585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
Study NCT05148585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity-based therapy
Description: patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
Study NCT00195260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
Study NCT00195260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: 400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
Study NCT02049866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
Study NCT04024631 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 75g glucose beverage (Glucola, Trutol, or similar brand)
Description: Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
Study NCT01882998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended repeat HIV testing and enhanced counseling
Description: Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
Study NCT03559244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic compression brace
Description: custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
Study NCT03559244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
Study NCT04024631 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DXA, whole body
Description: Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
Study NCT00269516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pardoprunox
Description: fixed dose 6 mg
Study NCT00269516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: fixed dose 12 mg
Study NCT03559244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
Study NCT03119116 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
Study NCT03119116 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
Study NCT03119116 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
Study NCT03860311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder Ultrasound
Description: Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound.
Study NCT02327793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Study NCT03860311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
Study NCT00269516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12-42mg
Study NCT01886131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronised video-polysomnography
Description: We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task.
Study NCT03118531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)
Description: The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
Study NCT03734367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional abilities training program
Description: A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
Study NCT00269516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00641654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
Study NCT00641654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
Study NCT02327793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Study NCT02611011 — intervention group
Intervention type: DEVICE
Intervention: Congo Red Test (GV-005)
Description: The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
Study NCT00641654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
Study NCT03426683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intestinal Microbiota Transplantation
Description: the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
Study NCT02783235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cervical cancer screening
Description: for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
Study NCT02828423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMD
Description: Regenerative surgery with EMD
Study NCT02828423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMD
Description: Regenerative surgery with EMD
Study NCT02679313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoropter
Description: Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
Study NCT02828423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BC
Description: Regenerative surgery with BC
Study NCT02873728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
Study NCT02873728 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
Study NCT04955041 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: T2\* MRI
Study NCT03084770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological imaging studies
Description: Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67> 2%) a high quality imaging (CT scan or MRI) is required.
Study NCT04523441 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: Holding of a focus group by a sociologist
Study NCT04523441 — intervention group
Intervention type: OTHER
Intervention: Semi-directive interview
Description: Conducting a semi-directive interview by a sociologist after discharge from hospital
Study NCT03084770 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Assessment
Description: quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
Study NCT04488796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Strategies: Opt-in
Description: Participants will be assigned two behavioural strategies with the opt-in choice structure
Study NCT04488796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Strategies: Active Choice
Description: Participants will be assigned two behavioural strategies with the Active choice structure
Study NCT04488796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Strategies: Enhanced Active Choice
Description: Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
Study NCT04488796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice of Assignment: Opt-in
Description: Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
Study NCT04488796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice of Assignment: Active Choice
Description: Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
Study NCT04488796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice of Assignment: Enhanced Active Choice
Description: Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
Study NCT03760848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aramchol
Description: Aramchol 600 mg
Study NCT03760848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam 2 mg
Study NCT03760848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: atorvastatin 40 mg
Study NCT01294891 — intervention group
Intervention type: OTHER
Intervention: Imaging
Description: Contrast ultrasound perfusion imaging and complete echocardiography
Study NCT02242994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynavox Maestro
Description: Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
Study NCT02242994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental App
Description: Participant receives experimental app to test speed and error rate of communication.
Study NCT02001116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement intervention
Description: 1. Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~2. Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care
Study NCT04229498 — intervention group
Intervention type: DRUG
Intervention: Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
Description: In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
Study NCT02153450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO
Study NCT02153450 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT00715611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurectomy/Decortication
Description: Pleurectomy/decortication will be performed as per standard technique
Study NCT00715611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed and cisplatin or carboplatin
Description: The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
Study NCT00715611 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
Study NCT00338858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking and balance performance evaluation
Study NCT00338858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking and balance performance evaluation
Study NCT00338858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle strength, walking and balance performance
Description: HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
Study NCT00338858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle strength, walking and balance performance
Description: HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
Study NCT02823106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil and Citicoline
Description: Single dosing strategy will be used.
Study NCT02823106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single matching dosing strategy will be used.
Study NCT02607384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eyeglass wearing
Description: Children found to require eyeglasses will be given two pairs free of charge
Study NCT04425239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Continuous administation
Study NCT04425239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Intermittent administation
Study NCT02607384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orthoptic exercises
Description: Children found to have convergence insufficiency will be prescribed orthoptic exercises
Study NCT02607384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialist referral
Description: Children found to any other eye condition will be referred to a pediatric eye care specialist
Study NCT04147702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance analysis
Description: Balance analysis is assessment method to estimate deterioration of postural control.
Study NCT01846312 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: The participants will not receive any treatment.
Study NCT01833507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Exercise
Description: Behavioral Goal Setting
Study NCT01833507 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
Study NCT01262105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System Device
Description: Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
Study NCT02740985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
Study NCT04147702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance analysis
Description: Balance analysis is assessment method to estimate deterioration of postural control.
Study NCT00392860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural-Fit
Description: Ergonomic handrim for wheelchairs
Study NCT00392860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PalmRim
Description: Ergonomic handrim for wheelchair
Study NCT00392860 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Handrim Control Group
Description: Participants were given a new standard handrim to test. This intervention group is the control group.
Study NCT04383483 — intervention group
Intervention type: OTHER
Intervention: COVICU
Description: COVICU
Study NCT03879278 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NPT189
Description: NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
Study NCT03415568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LCT oil
Description: LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
Study NCT03415568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCDG oil
Description: MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
Study NCT02940912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine
Description: cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
Study NCT02940912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
Study NCT02740985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
Study NCT02740985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets.
Study NCT03307642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message notification
Description: Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication